Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03993912 | Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy(IFM2017_03) | completed | Phase 3 | 294 | University Hospital, LilleOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01309334 | Imaging Young Myeloma (IMAgerie JEune Myélome)(IMAJEM) | completed | Phase 3 | 152 | Nantes University HospitalOTHER |
| 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT01971658 | Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)(IFM2013-04) | completed | Phase 3 | 358 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01827605 | A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) | completed | Phase 3 | 159 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04008706 | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients(ASSURE) | completed | Phase 3 | 552 | AstraZenecaINDUSTRY | 17 | Sep 1, 2026 | clinicaltrials |
| NCT04939142 | A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)(BENCH) | completed | Phase 3 | 154 | Antengene CorporationINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05184088 | Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis(CArdiag) | completed | Phase 3 | 244 | Lantheus Germany GmbHINDUSTRY | 4 | Aug 3, 2026 | clinicaltrials |
| NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | completed | Phase 3 | 21 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03901963 | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant(AURIGA) | completed | Phase 3 | 200 | Janssen Research & Development, LLCINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT03651128 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(KarMMa-3) | completed | Phase 3 | 386 | CelgeneINDUSTRY | 13 | Jun 22, 2026 | clinicaltrials |
| NCT04833114 | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)(Pola-R-ICE) | completed | Phase 3 | 306 | GWT-TUD GmbHOTHER | 4 | Jun 10, 2026 | clinicaltrials |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | completed | Phase 3 | 390 | Janssen Research & Development, LLCINDUSTRY | 24 | Jun 8, 2026 | clinicaltrials |
| NCT03652064 | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | completed | Phase 3 | 395 | Janssen Research & Development, LLCINDUSTRY | 13 | Jun 2, 2026 | clinicaltrials |
| NCT03891914 | Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma(MYELOCHOL) | completed | Phase 3 | 20 | University Hospital, BordeauxOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL(DEB) | completed | Phase 3 | 423 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00430365 | Maintenance Therapy Using Lenalidomide in Myeloma(IFM2005-02) | completed | Phase 3 | 614 | University Hospital, ToulouseOTHER | 3 | Apr 6, 2026 | clinicaltrials |
| NCT01191060 | Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years(IFM/DFCI2009) | completed | Phase 3 | 700 | University Hospital, ToulouseOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT00931645 | Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia(Auto-LLC 2001) | completed | Phase 3 | 241 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | completed | Phase 3 | 445 | Pharmacyclics LLC.INDUSTRY | 19 | Mar 17, 2026 | clinicaltrials |
| NCT05804032 | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 514 | University of Heidelberg Medical CenterOTHER | 2 | Feb 18, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma(ZUMA-7) | completed | Phase 3 | 359 | Kite, A Gilead CompanyINDUSTRY | 14 | Dec 1, 2025 | clinicaltrials |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 445 | Hoffmann-La RocheINDUSTRY | 21 | Nov 6, 2025 | clinicaltrials |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 737 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 20, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT01241708 | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma((Mel/MelVel)) | completed | Phase 3 | 148 | Hackensack Meridian HealthOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 498 | Janssen Research & Development, LLCINDUSTRY | 15 | Aug 29, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT02066454 | Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs(MYELAXAT) | completed | Phase 3 | 108 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | CelgeneINDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 569 | Janssen Research & Development, LLCINDUSTRY | 18 | May 1, 2025 | clinicaltrials |
| NCT03277105 | A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 522 | Janssen Research & Development, LLCINDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT01303887 | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients(PACIFICO) | completed | Phase 3 | 680 | University of LiverpoolOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02541383 | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma(Cassiopeia) | completed | Phase 3 | 1,085 | Intergroupe Francophone du MyelomeNETWORK | 3 | Apr 13, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 37 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04178798 | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 22 | PETHEMA FoundationOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | completed | Phase 3 | 623 | The Lymphoma Academic Research OrganisationOTHER | 7 | Mar 5, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials